STAT proteins as novel targets for cancer drug discovery

Expert Opinion on Therapeutic Targets

Volumn 8, Issue 5, 2004, Pages 409-422

  Turkson, James ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Drug targets; Inhibitors; Stat3; Stat5

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; GROWTH FACTOR; IMATINIB; INTERLEUKIN 6; MYC PROTEIN; ONCOPROTEIN; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SURVIVIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VASCULOTROPIN;

BRAIN CANCER; BREAST CANCER; CARCINOGENESIS; CELL ACTIVITY; CELL SURVIVAL; CELL TRANSFORMATION; CYTOPLASM; DISEASE ASSOCIATION; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; ESOPHAGUS CARCINOMA; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC REGULATION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MOUSE; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DRUG DESIGN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MILK PROTEINS; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT2 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; STAT6 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS;

EID: 5444237088     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.8.5.409     Document Type: Review

References (148)

1. DARNELL JE Jr: STATs and gene regulation. Science (1997) 277:1630-1635.
2. SCHINDLER C, DARNELL JE Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. (1995) 64:621-651.
3. BROMBERG J, DARNELL JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 19:2468-2473.
4. STARK GR, KERR IM, WILLIAMS BR, SILVERMAN RH, SCHREIBER RD: How cells respond to interferons. Annu. Rev. Biochem. (1998) 67:227-264.
5. SMITHGALL TE, BRIGGS SD, SCHREINER S et al.: Control of myeloid differentiation and survival by stats. Oncogene (2000) 19:2612-2618.
6. AKIRA S: Roles of STAT3 defined by tissue-specific gene targeting. Oncogene (2000) 19:2607-2611.
7. HIRANO T, ISHIHARA K, HIBI M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene (2000) 19:2548-2556.
8. KOTENKO SV, PESTKA S: Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene (2000) 19:2557-2565.
9. BROMBERG J: Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. (2000) 2:86-90.
10. SCHREIBER S, ROSENSTIEL P, HAMPE J et al.: Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut (2002) 51:379-385.
11. SCHINDLER CW: Series introduction. JAK-STAT signaling in human disease. J. Clin. Invest. (2002) 109:1133-1137.
12. YU H, JOVE R: The STATS of cancer - new molecular targets come of age. Nat. Rev. Cancer (2004) 4:97-105.
13. BUETTNER R, MORA LB, JOVE R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. (2002) 8:945-954.
14. TURKSON J, JOVE R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 19:6613-6626.
15. BOWMAN T, GARCIA R, TURKSON J, JOVE R: STATs in oncogenesis. Oncogene (2000) 19:2474-2488.
16. GARCIA R, JOVE R: Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. (1998) 5:79-85.
17. YU CL, MEYER DJ, CAMPBELL GS et al.: Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 269:81-83.
18. WATSON CJ, MILLER WR: Elevated levels of members of the STAT family of transcription factors in breast carcinoma nuclear extracts. Br. J. Cancer (1995) 71:840-844.
19. BESSER D, BROMBERG JF, DARNELL JE Jr, HANAFUSA H: A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol. Cell. Biol. (1999) 19:1401-1409.
20. ZONG CS, ZENG L, JIANG Y, SADOWSKI HB, WANG LH: Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J. Biol. Chem. (1998) 273:28065-28072.
21. GARCIA R, YU CL, HUDNALL A et al.: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. (1997) 8:1267-1276.
22. WEN X, LIN HH, SHIH HM, KUNG HJ, ANN DK: Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J. Biol. Chem. (1999) 274:38204-38210.
23. YU CL, JOVE R, BURAKOFF SJ: Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J. Immunol. (1997) 159:5206-5210.
24. LUND TC, PRATOR PC, MEDVECZKY MM, MEDVECZKY PG: The Lck binding domain of herpesvirus saimiri tip-484 constitutively activates Lck and STAT3 in T cells. J. Virol. (1999) 73:1689-1694.
25. MIGONE TS, LIN JX, CERESETO A et al.: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science (1995) 269:79-81.
26. WEBER-NORDT RM, EGEN C, WEHINGER J et al.: Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood (1996) 88:809-816.
27. LUND TC, GARCIA R, MEDVECZKY MM, JOVE R, MEDVECZKY PG: Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p561ck. J. Virol. (1997) 71:6677-6682.
28. NEPOMUCENO RR, SNOW AL, ROBERT BEATTY P, KRAMS SM, MARTINEZ OM: Constitutive activation of Jak/STAT proteins in Epstein-Barr virus-infected B-cell lines from patients with posttransplant lymphoproliferative disorder. Transplantation (2002) 74:396-402.
29. AKIRA S: Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells (1999) 17:138-146.
30. TURKSON J, BOWMAN T, GARCIA R et al.: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol. Cell. Biol. (1998) 18:2545-2552.
31. SHEN Y, DEVGAN G, DARNELL JE Jr, BROMBERG JF: Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc. Natl. Acad. Sci. USA (2001) 98:1543-1548.
32. SONG JI, GRANDIS JR: STAT signaling in head and neck cancer. Oncogene (2000) 19:2489-2495.
33. COFFER PJ, KOENDERMAN L, DE GROOT RP: The role of STATs in myeloid differentiation and leukemia. Oncogene (2000) 19:2511-2522.
34. LIN TS, MAHAJAN S, FRANK DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene (2000) 19:2496-2504.
35. CATLETT-FALCONE R, DALTON WS, JOVE R: STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr. Opin. Oncol. (1999) 11:490-496.
36. SARTOR CI, DZIUBINSKI ML, YU CL, JOVE R, ETHIER SP: Role of epidermal growth factor receptor and STAT3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. (1997) 57:978-987.
37. GARCIA R, BOWMAN TL, NIU G et al.: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 20:2499-2513.
38. PAGE C, HUANG M, JIN X et al.: Elevated phosphorylation of AKT and Stat3 in prostate, breast, and cervical cancer cells. Int. J. Oncol. (2000) 17:23-28.
39. BURKE WM, JIN X, LIN HJ et al.: Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene (2001) 20:7925-7934.
40. COTARLA I, REN S, ZHANG Y et al.: Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int. J. Cancer (2004) 108:665-671.
41. REAL PJ, SIERRA A, DE JUAN A et al.: Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene (2002) 21:7611-7618.
42. LI L, SHAW PE: Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J. Biol. Chem. (2002) 277:17397-17405.
43. GRITSKO T, TURKSON J, KANEKO S et al.: Persistent activation of Stat3 signaling induces Survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. (2004) (In Press).
44. BERCLAZ G, ALTERMATT HJ, ROHRBACH V et al.: EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int. J. Oncol. (2001) 19:1155-1160.
45. YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. (2001) 2:127-137.
46. CATALDO L, CHEN NY, YUAN Q et al.: Inhibition of Oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells. Int. J. Oncol. (2000) 17:1179-1185.
47. LLOVERA M, PICHARD C, BERNICHTEIN S et al.: Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene (2000) 19:4695-4705.
48. KAULSAY KK, MERTANI HC, TORNELL J et al.: Autocrine stimulation of the human mammary carcinoma cell proliferation by human growth hormone. Exp. Cell Res. (1999) 250:35-50.
49. RICHER JK, LANGE CA, MANNING NG et al.: Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J. Biol. Chem. (1998) 273:31317-31326.
50. GRANT SL, HAMMACHER A, DOUGLAS AM et al.: An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene (2002) 21:460-474.
51. BADACHE A, HYNES NE: Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res. (2001) 61:383-391.
52. GRANDIS JR, DRENNING SD, ZENG Q et al.: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:4227-4232.
53. GRANDIS JR, DRENNING SD, CHAKRABORTY A et al.: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. (1998) 102:1385-1392.
54. LEONG PL, XI S, DRENNING SD et al.: Differential function of STAT5 isoforms in head and neck cancer growth control. Oncogene (2002) 21:2846-2853.
55. NAGPAL JK, MISHRA R, DAS BR: Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer (2002) 94:2393-2400.
56. GRANDIS JR, ZENG Q, DRENNING SD: Epidermal growth factor receptor-mediated Stat3 signaling blocks apoptosis in head and neck cancer. Laryngoscope (2000) 110:868-874.
57. LEONG PL, ANDREWS GA, JOHNSON DE et al.: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA (2003) 100:4138-4143.
58. KIJIMA T, NIWA H, STEINMAN RA et al.: STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. (2002) 13:355-362.
59. MASUDA M, SUZUI M, YASUMATU R et al.: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin d1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. (2002) 62:3351-3355.
60. XI S, ZHANG Q, DYER KF et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J. Biol. Chem. (2003) 278:31574-31583.
61. SRIURANPONG V, PARK JI, AMORNPHIMOLTHAM P et al.: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. (2003) 63:2948-2956.
62. NIU G, HELLER R, CATLETT-FALCONE R et al.: Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. (1999) 59:5059-5063.
63. NIU G, SHAIN K, HUANG M et al.: Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. (2001) 61:3276-3280.
64. NIU G, BOWMAN T, HUANG M et al.: Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 21:7001-7010.
65. KIRKWOOD JM, FARKAS DL, CHAKRABORTY A et al.: Systemic interferon-α (IFN-α) treatment leads to stat3 inactivation in melanoma precursor lesions. Mol. Med. (1999) 5:11-20.
66. NIU G, WRIGHT KL, HUANG M et al.: Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 21:2000-2008.
67. KRASIL'NIKOV M, SHATSKAYA V: Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J. Steroid Biochem. Mol. Biol. (2002) 82:369-376.
68. WELLBROCK C, GEISSINGER E, GOMEZ A et al.: Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma. Oncogene (1998) 16:3047-3056.
69. MORCINEK JC, WEISSER C, GEISSINGER E, SCHARTL M, WELLBROCK C: Activation of STAT5 triggers proliferation and contributes to anti-apoptotic signalling mediated by the oncogenic Xmrk kinase. Oncogene (2002) 21:1668-1678.
70. NI Z, LOU W, LEMAN ES, GAO AC: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. (2000) 60:1225-1228.
71. GAO B, SHEN X, KUNOS G et al.: Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. (2001) 488:179-184.
72. MORA LB, BUETTNER R, SEIGNE J et al.: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. (2002) 62:6659-6666.
73. DHIR R, NI Z, LOU W et al.: Stat3 activation in prostatic carcinomas. Prostate (2002) 51:241-246.
74. CAMPBELL CL, JIANG Z, SAVARESE DM, SAVARESE TM: Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am. J. Pathol. (2001) 158:25-32.
75. BARTON BE, MURPHY TF, ADEM P et al.: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer (2001) 1:19.
76. BARTON BE, KARRAS JG, MURPHY TF, BARTON A, HUANG HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. (2004) 3:11-20.
77. NI Z, LOU W, LEE SO et al.: Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J. Urol. (2002) 167:1859-1862.
78. SMITH PC, HOBISCH A, LIN DL, CULIG Z, KELLER ET: Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev. (2001) 12:33-40.
79. LEE SO, LOU W, HOU M et al.: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. (2003) 9:370-376.
80. LOU W, NI Z, DYER K, TWEARDY DJ, GAO AC: Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate (2000) 42:239-242.
81. SEKHARAM M, TURKSON J, JOVE R, CALVIN D: Radiosensitization of prostate cancer cell line, DU 145 by novel Stat3 inhibitor, CPA-7. J. Exp. Ther. Oncol. (2004) (In press).
82. CATTANEO E, MAGRASSI L, DE-FRAJA C et al.: Variations in the levels of the JAK/STAT and ShcA proteins in human brain tumors. Anticancer Res. (1998) 18:2381-2387.
83. SCHAEFER LK, REN Z, FULLER GN, SCHAEFER TS: Constitutive activation of Stat3α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene (2002) 21:2058-2065.
84. RAHAMAN SO, HARBOR PC, CHERNOVA O et al.: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 21:8404-8413.
85. KONNIKOVA L, KOTECKI M, KRUGER MM, COCHRAN BH: Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer (2003) 3:23.
86. PAILLAUD E, COSTA S, FAGES C et al.: Retinoic acid increases proliferation rate of GL-15 glioma cells, involving activation of STAT-3 transcription factor. J. Neurosci. Res. (2002) 67:670-679.
87. REBBAA A, CHOU PM, MIRKIN BL: Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol. Med. (2001) 7:393-400.
88. SCHAEFER LK, MENTER DG, SCHAEFER TS: Activation of Stat3 and Stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell. Signal. (2000) 12:143-151.
89. LI B, CHANG CM, YUAN M, MCKENNA WG, SHU HK: Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. (2003) 63:7443-7450.
90. ZHANG Q, NOWAK I, VONDERHEID EC et al.: Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA (1996) 93:9148-9153.
91. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 10:105-115.
92. ERIKSEN KW, KALTOFT K, MIKKELSEN G et al.: Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia (2001) 15:787-793.
93. EPLING-BURNETTE PK, LUI JH, CATLETTE-FALCONE R et al.: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. (2001) 107:351-362.
94. KIRITO K, NAGASHIMA T, OZAWA K, KOMATSU N: Constitutive activation of Stat1 and Stat3 in primary erythroleukemia cells. Int. J. Hematol. (2002) 75:51-54.
95. SPIEKERMANN K, BIETHAHN S, WILDE S, HIDDEMANN W, ALVES F: Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur. J. Haematol. (2001) 67:63-71.
96. QUINTANILLA-MARTINEZ L, KREMER M, SPECHT K et al.: Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am. J. Pathol. (2003) 162:1449-1461.
97. ZHANG Q, RAGHUNATH PN, XUE L et al.: Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J. Immunol. (2002) 168:466-474.
98. HODGE DR, XIAO W, WANG LH, LI D, FARRAR WL: Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol. Ther. (2004) 3:2.
99. BURGER R, BAKKER F, GUENTHER A et al.: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br. J. Haematol. (2003) 123:869-878.
100. ALAS S, BONAVIDA B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. (2001) 61:5137-5144.
101. GALM O, YOSHIKAWA H, ESTELLER M, OSIEKA R, HERMAN JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2003) 101:2784-2788.
102. CHEN CY, TSAY W, TANG JL et al.: SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer (2003) 37:300-305.
103. CHENG J, ZHANG D, ZHOU C, MARASCO WA: Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells. Leuk. Res. (2004) 28:71-82.
104. ZAMO A, CHIARLE R, PIVA R et al.: Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene (2002) 21:1038-1047.
105. SPIEKERMANN K, PAU M, SCHWAB R et al.: Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp. Hematol. (2002) 30:262-271.
106. HORITA M, ANDREU EJ, BENITO A et al.: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. (2000) 191:977-984.
107. HUANG M, DORSEY JF, EPLING-BURNETTE PK et al.: Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 21:8804-8816.
108. GESBERT F, GRIFFIN JD: Bcr/Abl activates transcription of the Bcl-X gene through STAT5. Blood (2000) 96:2269-2276.
109. NIELSEN M, KAESTEL CG, ERIKSEN KW et al.: Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia (1999) 13:735-738.
110. PUTHIER D, BATAILLE R, AMIOT M: IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. (1999) 29:3945-3950.
111. PUTHIER D, THABARD W, RAPP M et al.: Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br. J. Haematol. (2001) 112:358-363.
112. PANER GP, SILBERMAN S, HARTMAN G et al.: Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors. Anticancer Res. (2003) 23:2253-2260.
113. HORIGUCHI A, OYA M, MARUMO K, MURAI M: STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int. (2002) 61:926-938.
114. LEU CM, WONG FH, CHANG C, HUANG SF, HU CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene (2003) 22:7809-7818.
115. WEI D, LE X, ZHANG L et al.: Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 22:319-329.
116. DEARMOND D, BRATTAIN MG, JESSUP JM et al.: Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene (2003) 22:7781-7795.
117. WEI LH, KUO ML, CHEN CA et al.: The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI3-K/Akt pathway. Oncogene (2001) 20:5799-5809.
118. HUANG M, PAGE C, REYNOLDS RK, LIN J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol. Oncol. (2000) 79:67-73.
119. KANAI M, KONDA Y, NAKAJIMA T et al.: Differentiation-inducing factor-1 (DIF-1) inhibits STAT3 activity involved in gastric cancer cell proliferation via MEK-ERK-dependent pathway. Oncogene (2003) 22:548-554.
120. COLLUM RG, BRUTSAERT S, LEE G, SCHINDLER C: A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc. Natl. Acad. Sci. USA (2000) 97:10120-10125.
121. CALO V, MIGLIAVACCA M, BAZAN V et al.: STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. (2003) 197:157-168.
122. KILE BT, NICOLA NA, ALEXANDER WS: Negative regulators of cytokine signaling. Int. J. Hematol. (2001) 73:292-298.
123. SHUAI K: Modulation of STAT signaling by STAT-interacting proteins. Oncogene (2000) 21:2638-2644.
124. YASUKAWA H, SASAKI A, YOSHIMURA A: Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. (2000) 18:143-164.
125. CHEN XP, LOSMAN JA, ROTHMAN P: SOCS proteins, regulators of intracellular signaling. Immunity (2000) 13:287-290.
126. SHUAI K: The STAT family of proteins in cytokine signaling. Prog. Biophys. Mol. Biol. (1999) 71:405-422.
127. NAGAI H, KIM YS, KONISHI N et al.: Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett. (2002) 186:59-65.
128. YOSHIKAWA H, MATSUBARA K, QIAN GS et al.: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. (2001) 28:29-35.
129. SINIBALDI N, WHARTON W, TURKSON J et al.: Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene (2000) 19:5419-5427.
130. BROMBERG JF, WRZESZCZYNSKA MH, DEVGAN G et al.: Stat3 as an oncogene. Cell (1999) 98:295-303.
131. AOKI Y, FELDMAN GM, TOSATO G: Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood (2003) 101:1535-1542.
132. WANG T, NIU G, KORTYLEWSKI M et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. (2004) 10:48-54.
133. OSHIRO MM, LANDOWSKI TH, CATLETT-FALCONE R et al.: Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin. Cancer Res. (2001) 7:4262-4271.
134. BLASKOVICH MA, SUN J, CANTOR A et al.: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. (2003) 63:1270-1279.
135. SEBTI S: New drug targets and therapies for cancer. Oncol. Rev. (2000) 19:6549-6692.
136. DANCEY JE: Recent advances of molecular targeted agents: opportunities for imaging. Cancer Biol. Ther. (2003) 2:601-609.
137. TURKSON J, KIM JS, ZHANG S et al.: Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. (2004) 3:261-269.
138. TURKSON J, ZHANG S, PALMER J et al.: Inhibition of constitutive Stat3 activation by novel platinum complexes with potent anti-tumor activity. Mol. Cancer Ther. (2004) (In press).
139. TURKSON J, RYAN D, KIM JS et al.: Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. (2001) 276:45443-45455.
140. SHUAI K, STARK GR, KERR IM, DARNELL JE Jr: A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ. Science (1993) 261:1744-1746.
141. SHUAI K, HORVATH CM, HUANG LH et al.: Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell (1994) 76:821-828.
142. SCHAEFER TS, SANDERS LK, PARK OK, NATHANS D: Functional differences between Stat3α and Stat3β. Mol. Cell. Biol. (1997) 17:5307-5316.
143. SASSE J, HEMMANN U, SCHWARTZ C et al.: Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol. Cell. Biol. (1997) 17:4677-4686.
144. BECKER S, GRONER B, MULLER CW: Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature (1998) 394:145-151.
145. REN Z, CABELL LA, SCHAEFER TS, MCMURRAY JS: Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. (2003) 13:633-636.
146. NAGEL-WOLFRUM K, BUERGER C, WITTIG I et al.: The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol. Cancer Res. (2004) 2:170-182.
147. JING N, LI Y, XU X et al.: Targeting Stat3 with G-quartet oligodeoxynucleotides in human cancer cells. DNA Cell Biol. (2003) 22:685-696.
148. BERG T, COHEN SB, DESHARNAIS J et al.: Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA (2002) 99:3830-3835.